Nice. So Pulmozyme inadvertently makes Bronchitol more affordable. On a slightly different tack, I always thought that if PXS were prepared to spend the money on a second go with the FDA (which is not a light expense) then they must figure there's a decent return in it from thereon. $4M worldwide is not much at all, so there must be more to this than meets the eye. Otherwise, why would they sink so much into getting FDA approval.
a kicker for bronchitol revenues, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
